Kenya’s partnership with pharmaceutical giant Pfizer has become an important development in the country’s efforts to make medicines and vaccines more affordable and strengthen the health system. The partnership is particularly significant because it is not limited to the supply of medicines. It also touches on vaccines, healthcare supply chains, regulation, health-worker development, research, clinical trials, technology transfer and the possibility of strengthening local pharmaceutical manufacturing.

The Kenya–Pfizer relationship gained major attention in June 2025, when the Ministry of Health officially launched the Kenya–Pfizer Accord under Pfizer’s Accord for a Healthier World initiative. The agreement was designed to improve access to medicines in Kenya’s public health system, particularly for diseases such as cancer, diabetes and infectious diseases. According to Kenya’s Ministry of Health, the arrangement gives the country access to more than 140 medicines on a not-for-profit basis, with some medicines expected to cost substantially less than they would under normal commercial arrangements. 

The partnership has since expanded. In 2026, Kenya and Pfizer reviewed implementation of their Memorandum of Understanding and discussed taking the relationship beyond medicine access to include clinical research, technology transfer, local manufacturing and regional pharmaceutical distribution. The MoU took effect in April 2025 and was renewed in May 2026. 

Background to the Kenya–Pfizer partnership

The partnership is connected to Pfizer’s Accord for a Healthier World, a global initiative intended to increase access to selected medicines in lower-income countries on a not-for-profit basis.

Kenya has for years faced challenges involving the cost and availability of medicines. Although the country has a large public healthcare network, patients can still experience difficulties obtaining medicines, particularly expensive treatments for chronic and serious diseases.

Cancer treatment is one of the areas where the problem is particularly severe. Some cancer medicines are extremely expensive, and the financial burden can force families to sell property, borrow money or interrupt treatment.

The Ministry of Health therefore views partnerships such as the one with Pfizer as part of the broader effort to achieve Universal Health Coverage (UHC).

In June 2025, Health officials said the Kenya–Pfizer Accord could reduce the cost of more than 140 essential medicines by as much as 60 percent. The medicines include treatments for cancer, diabetes and infectious diseases. 

The agreement was presented as a way of reducing the financial burden on patients while strengthening Kenya's public healthcare system.

What the agreement provides

One of the most important aspects of the agreement is access to Pfizer medicines at reduced, not-for-profit prices.

This is different from a normal commercial arrangement in which medicines are sold with the objective of generating profits. Under the Accord for a Healthier World framework, Pfizer makes selected medicines available to participating lower-income countries at prices intended to improve affordability.

For Kenya, the agreement covers a broad range of medicines. The Ministry of Health said more than 140 medicines would be available under the arrangement. These medicines are relevant to several major disease categories.

The partnership also covers vaccines, meaning its potential impact goes beyond treatment and into disease prevention. A review of the MoU in August 2026 confirmed that not-for-profit access to Pfizer medicines and vaccines remains one of the core elements of the relationship. 

Major breakthrough for cancer treatment

Cancer is arguably one of the areas where the Pfizer partnership could have the greatest impact.

On September 1, 2026, the National Cancer Institute of Kenya announced that a new agreement between the Kenyan Government and Pfizer could dramatically reduce the cost of selected cancer medicines.

According to the National Cancer Institute, some treatments that could previously cost as much as KSh1 million per treatment cycle may fall to below KSh50,000 under the new arrangement. That represents a potential reduction of more than seven times for some medicines. 

The medicines covered include treatments for several cancers, including:

Breast cancer

Stomach cancer

Colorectal cancer

Lung cancer

Prostate cancer

Oesophageal cancer

Leukaemia

Lymphoma

Multiple myeloma

This development is particularly important because cancer treatment can involve several cycles of chemotherapy, targeted therapy or other medicines. When each treatment cycle is expensive, the overall cost can become unaffordable for ordinary households.

The new arrangement could therefore make it possible for more patients to complete treatment rather than stopping because of financial difficulties.

Connection with the Social Health Authority

Another important aspect is the relationship between the Pfizer agreement and Kenya's Social Health Authority (SHA).

Kenya has been implementing SHA as part of the government's reforms of health financing and Universal Health Coverage.

The National Cancer Institute said the lower medicine prices could help the SHA's KSh800,000 cancer package cover treatment more effectively. If medicines that previously consumed a large portion of the available cancer-treatment funding become significantly cheaper, the same public resources could potentially support more patients. 

This does not mean every cancer patient will automatically receive unlimited treatment without additional costs. Actual coverage will depend on the applicable SHA benefits, clinical requirements, approved medicines and implementation arrangements.

Nevertheless, lower medicine prices could make the health insurance system more sustainable because expensive medicines are among the major costs associated with managing serious illnesses.

Strengthening Kenya's medicine supply chain

The partnership is also concerned with how medicines move from manufacturers to patients.

A medicine can be affordable at the manufacturer level but still fail to reach patients if procurement, storage and distribution systems are weak.

This is why Kenya Medical Supplies Authority (KEMSA) has become an important part of the discussions.

In September 2025, KEMSA held high-level discussions with Pfizer's Accord supply-chain team. The discussions focused on closing supply-chain gaps, improving last-mile delivery and using Pfizer's international supply-chain expertise to strengthen Kenya's system. 

Kenya Medical Supplies Authority - KEMSA

KEMSA has also been undertaking operational reforms, including automation and system upgrades.

The Ministry of Health has highlighted the importance of improving order fulfilment within KEMSA. In 2025, the Ministry said it wanted to raise order fulfilment rates from about 47 percent to 100 percent. 

If these reforms succeed, the benefit of cheaper medicines could reach more hospitals and patients across the country.

Local pharmaceutical manufacturing

Perhaps the most ambitious part of the expanded partnership is Kenya's desire to move from being primarily a consumer and importer of medicines to becoming a stronger pharmaceutical manufacturing centre.

Kenya's Ministry of Health has indicated that it wants the Pfizer relationship to support technology transfer and local manufacturing.

This is important because Kenya imports a significant proportion of its medicines and medical products. Heavy dependence on imports can expose the country to international supply disruptions, foreign exchange pressures and global shortages.

Local manufacturing could help Kenya develop greater self-reliance.

The discussions in 2026 included the possibility of Pfizer supporting relevant technologies and newer medicines in ways that could contribute to pharmaceutical production in Africa. Kenya has also linked the partnership to its Health Products and Technologies Local Manufacturing Strategy 2026–2030. 

However, technology transfer and local manufacturing are longer-term goals. They require investment, regulatory capacity, skilled workers, manufacturing facilities and sustainable markets. The agreement should therefore not be interpreted as meaning that Pfizer medicines will immediately begin being manufactured locally in Kenya.

Clinical trials and medical research

Kenya is also interested in expanding the relationship into clinical research and clinical trials.

Clinical trials are important because they allow new medicines and treatments to be evaluated in patients under controlled scientific conditions.

Kenya already has a growing research and medical-science sector, and increased collaboration with international pharmaceutical companies could potentially create opportunities for Kenyan researchers, doctors, hospitals and universities.

The Ministry of Health has specifically called for the Kenya–Pfizer partnership to support clinical trials and research infrastructure. 

If properly managed, such collaboration could bring several benefits, including increased research capacity, professional training and earlier access to innovative therapies.

At the same time, clinical research must be conducted under strict ethical and regulatory requirements to protect participants.

Regulatory cooperation

Another pillar of the agreement is regulatory collaboration.

Medicines and vaccines must go through regulatory processes before they can be supplied to patients. In Kenya, the Pharmacy and Poisons Board plays a key role in regulating pharmaceutical products.

The partnership provides an opportunity for Kenya and Pfizer to work on more efficient regulatory pathways while maintaining safety standards.

The government has also proposed stronger coordination between Pfizer, the Ministry of Health, KEMSA, the Pharmacy and Poisons Board and other government agencies.

This is important because faster regulatory processes can help patients gain access to new medicines sooner, but speed cannot come at the expense of medicine safety and quality.

Health-worker development

The agreement also has a human-resource component.

Kenya's healthcare system depends heavily on doctors, nurses, pharmacists, laboratory professionals and other healthcare workers.

The Ministry of Health has indicated that the broader partnership includes health workforce development. Earlier discussions with Pfizer also focused on healthcare workforce development, supply chains and regulatory systems. 

This means the partnership is increasingly being viewed as a health-system collaboration rather than simply a medicine procurement deal.

Kenya as a regional pharmaceutical hub

Kenya also wants to position itself as a logistics and distribution hub for East Africa.

The country's geographical position, transport infrastructure and relatively developed pharmaceutical sector give it potential to serve neighbouring countries.

If Kenya succeeds in strengthening pharmaceutical manufacturing, storage, distribution and regulation, the country could become an important regional centre for health products.

The Ministry of Health has therefore encouraged Pfizer to consider Kenya not only as a market for medicines but also as a possible regional base for manufacturing, research and distribution. 

Joint Coordination Committee

Another important feature of the agreement is the planned Joint Coordination Committee.

Such a committee is important because large health partnerships require regular monitoring.

The committee is expected to bring together relevant stakeholders, including the Ministry of Health, Pfizer, KEMSA and the Pharmacy and Poisons Board.

Its role is expected to include monitoring implementation, coordinating activities and assessing progress.

The government has emphasized the need to operationalise the committee so that the partnership can move from commitments and discussions to measurable results. 

What the agreement could mean for ordinary Kenyans

For ordinary Kenyans, the biggest potential benefit is lower healthcare costs.

A patient who previously could not afford a particular medicine may be able to obtain it through the public healthcare system at a substantially lower cost.

Cancer patients could be among the biggest beneficiaries, particularly if the reported reductions in treatment costs are implemented effectively.

The partnership could also improve access to vaccines and innovative medicines.

For families, lower medicine prices could reduce out-of-pocket spending. For the government, cheaper medicines could mean that limited healthcare resources serve more people.

Hospitals could also benefit if medicine availability and supply-chain systems improve.

Challenges and concerns

Despite the potential benefits, the agreement will not automatically solve all of Kenya's healthcare problems.

One major challenge is implementation.

An agreement can promise affordable medicines, but the real test is whether patients in counties outside Nairobi can actually obtain them when needed.

Another issue is supply-chain efficiency. Even inexpensive medicines are of little benefit if they are unavailable at hospitals.

There is also the question of sustainable financing. Kenya must ensure that the health financing system, including SHA, can reliably pay for medicines and treatments.

Local manufacturing will also require significant investment and technical capacity.

Finally, partnerships between governments and multinational pharmaceutical companies require transparency and accountability. The public needs clear information about pricing, procurement, distribution, eligibility and performance so that the benefits can be measured.

The bigger picture

The Kenya–Pfizer partnership represents a shift from viewing pharmaceutical companies simply as medicine suppliers toward a broader model of health-system collaboration.

Initially, the major focus was access to affordable medicines. The partnership has since expanded into vaccines, supply chains, regulatory cooperation and health-worker development. Kenya is now pushing for clinical research, technology transfer, local manufacturing and regional distribution. 

The cancer-treatment component announced in September 2026 has further increased the importance of the partnership, particularly because of the possibility of dramatically reducing the price of selected cancer medicines. 

If successfully implemented, the agreement could help Kenya reduce the cost of treating serious diseases, improve access to innovative medicines, strengthen pharmaceutical supply chains and build local capacity.

However, its success will ultimately be judged not by the number of agreements signed, but by whether medicines actually become available, affordable and accessible to patients across Kenya.